Projects

PRNDs: The Global Health Burden

Neglected diseases such as malaria, TB and sleeping sickness – as well as lesser-known worm and parasitic infections – kill 6 million people every year and disproportionately affect people living in the world's poorest countries. Europe is a vital source of R&D funding for neglected diseases and this needs to be sustained to save lives. Investing in R&D for these diseases also makes sense for Europe:

  • Europe has 30,000 new cases of HIV a year and 150 new cases of TB every day
  • 66 cents of each euro invested by the EU for these diseases is spent within the EU

This factsheet explains why neglected diseases are an issue Europe can’t afford to ignore.

Australia's Global Health R&D Investment: Achieving its Potential (2014)

Australia is a top funder of neglected disease R&D, ranking 6th globally in 2012. However, this funding is imbalanced, favouring some diseases and R&D areas more than others. There are waiting opportunities for Australia to make the greatest impact possible in the fight against those diseases that afflict the world’s poorest. This factsheet:

  • Maps Australia’s contribution to global health R&D
  • Outlines weaknesses in existing funding patterns
  • Recommends ways Australia can create even greater impact

Tuberculosis: The Last Mile (2014)

Current drugs, diagnostics and vaccines to fight tuberculosis (TB) are often ineffective and out-of-date. The WHO has acknowledged that new TB tools are urgently needed to significantly reduce TB deaths in the developing world. There is hope however, with investment in recent years leading to a number of promising new products moving into the late stages of development. These products have the potential to change lives for the millions worldwide who live with or are at risk of TB. This report:

  • Explains why current approaches to TB control aren’t working
  • Provides a snapshot of the major funders for TB R&D
  • Outlines what new products are in the TB pipeline, and how these could change the future for those with TB

Government Funding for Neglected Diseases: Why it Doesn't Add Up (2014)

Every year, more than 6 million people in low- and middle-income countries die from neglected diseases, for which the vaccines, medicines and diagnostic tests are either ineffective or completely lacking. This factsheet reviews government funding of the research and development (R&D) needed to make these missing products, including:

  • Which governments and agencies provide funding and how much
  • Who gets the funding, and why this matters
  • Why government funding for neglected disease R&D increasingly doesn’t add up

An Emerging Leader: Germany’s Role in Neglected and Poverty-related Disease R&D (2013)

Germany is now the fourth biggest public funder of neglected disease R&D globally in absolute terms however, in terms of its spend as a percentage of GDP (in 2012), it ranks below many other European countries including UK, France, Sweden, Ireland, the Netherlands and Switzerland.

Germany has a strong scientific history and a network of highly regarded research institutes active in R&D. As a G8 economy, Germany has the economic potential, unlike some of its European counterparts struggling to respond to the global economic crisis, to boost its neglected disease R&D funding and to capitalise on its R&D strengths. This report (also in German):

  • Analyses German public funding from 2007-2012
  • Gives a who’s-who of German public funders and research institutes
  • Summarises neglected disease R&D achievements to date and funding opportunities for the future
G-FINDER Factsheet

G-FINDER Diagnostic R&D for Neglected Diseases (2013)

Effective diagnostics are essential tools for the control, elimination and eradication of neglected diseases, with the ability to quickly and accurately identify infections critical to ensuring that patients receive the treatment they need and halting the further spread of disease. One of the great challenges to monitoring disease emergence and delivering appropriate control measures is the lack of readily available, easy-to-use, reliable and low-cost diagnostic tools. Despite the pressing need for new diagnostics, and the obvious advantages to developing effective diagnostic tools, current funding levels for research and development of new diagnostics are insufficient to meet the needs of many neglected diseases.

This factsheet examines funding of diagnostic research and development globally, based on G-FINDER data, and discusses the urgent need to rationalise funding, diversify funding sources and increase priority driven investments.

G-FINDER Factsheet

G-FINDER R&D for Diarrhoeal Diseases (2013)

Diarrhoea is one of the six conditions identified in the fourth Millennium Development Goal: reduce child mortality, that lead to the majority of child deaths. In 2010, diarrhoeal diseases caused 1.1 million deaths and 66.5 million years of productive life lost in developing countries. Whilst preventive measures such as clean drinking water and sanitation can reduce the risk of infection, research and development (R&D) of new tools is equally important, particularly for vaccines as they can prevent infection.

This factsheet examines funding for diarrhoeal disease R&D globally from 2007-2011 and discusses the need to increase the focus on under-funded disease areas, diversify funding sources and balance funding distribution between basic research and product development.

From Pipeline to Product: Malaria R&D Funding Needs (2013)

Malaria kills half a million people each year worldwide—and challenges such as drug resistance continue to emerge. Overcoming these challenges and combating malaria will rely on research and development (R&D) of new pharmaceutical products. From Pipeline to Product estimates the funding needed over the next decade for R&D of new tools to control, eliminate and eradicate malaria. The report analyses:

  • Which products need the most R&D funding
  • What’s in today’s malaria pipelines
  • Where funding is falling behind and where it’s on track

Download From Pipeline to Product summary here (4.46Mb)

Estimating Costs and Measuring Investments in Malaria R&D for Eradication (2013)

Within the larger landscape set out in From Pipeline to Product, this companion report focuses in on the specific subset of R&D aimed at eliminating and eradicating (E&E) malaria in the next decade. It explores funding for this relatively new target area for the first time, analysing:

  • The proportion of total malaria R&D funding going to E&E research and development
  • What products we’re likely to have in the next decade at current E&E funding levels
  • … and the investment needed to achieve the target E&E products requested by the global malaria community

Oil Search Health Foundation project (2013)

Policy Cures, in partnership with Nous Group, has been commissioned to develop a five-year strategic plan for the Oil Search Health Foundation (OSHF) to guide their contribution to health in Papua New Guinea (PNG). PNG is a hotspot within the Western Pacific for diseases such as tuberculosis and HIV/AIDS. Likewise, child and maternal health conditions are worryingly prevalent, particularly in rural areas, including lower respiratory infections, diarrheal diseases, meningitis and preterm birth complications.

OSHF is a not-for-profit charity set up in 2011 with the goal of improving the long term health and well-being of communities in PNG on behalf of its parent company, Oil Search Limited, an oil and gas company that has been operating in PNG since 1929.

DSW Report

Savings lives and creating impact: EU investment in poverty-related neglected diseases (2012)

Now is a critical time for European investment in R&D targeting poverty related neglected diseases (PRNDs). With European policymakers debating the eighth EU Framework Programme for Research and Innovation – Horizon 2020 – and with financial belt-tightening all round, it’s time to take stock. This report analyses the following issues:

  • Is Europe’s investment in PRNDs worthwhile?
  • What is the return on investment for the developing world and for Europe itself?
  • Does the European approach work?

Policy Cures has been commissioned to analyse these issues by The German Foundation for World Population (DSW) in Brussels. The report was launched in Brussels on September 26th 2012.

View the Powerpoint presentation in PDF

GHTC Report

Saving lives and creating impact: Why investing in global health research works (2012)

The United States Government has been at the forefront of the development of new technologies that have brought dramatic improvements in global health over the last half-century. Despite this, the global financial crisis and high levels of debt have led to pressure to scale back US government investment in global health research and development (R&D). There can also be a lack of recognition among some policy makers of the critical role R&D has played.

Financing

Innovative Financing Mechanisms (2012)

In South-East Asia, many people continue to die from preventable infectious diseases such as pneumonia, due to long delays between the advent of a new vaccine and its inclusion in the immunisation programmes of many countries. This ‘vaccine pile-up’ is likely to worsen in the coming decade as new vaccines become available for diseases like dengue, malaria and tuberculosis, and SE Asian countries need to find ways to finance them.

As part of the 2012 Asia-Pacific Development Summit, Policy Cures ran a workshop on ‘Financing for New Vaccines: Options for Asia’. The Policy Briefs below were developed for that workshop.

Policy Brief 1 - Lotteries
Policy Brief 2 - Global or Regional Taxes
Policy Brief 3 - Bonds Issues
Policy Brief 4 - Domestic Taxes
Policy Brief 5 - Low-Interest Multilateral Loans
Policy Brief 6 - Debt Conversion
Policy Brief 7 - Impact Investment Funds
Policy Brief 8 - Voluntary Consumer Contributions
Policy Brief 9 - Pooled Procurement

Optimal ARVs

Optimal ARVs for the developing world (2011)

Most people with HIV live in low-income countries (LICs) but the medicines that can save their lives—anti-retroviral therapies (ARVs)—are not always suited to their needs. In an ideal world, HIV-positive patients in LICs would have access to the best ARVs at the same time as they are available in the West, with these provided in LIC-suitable formulations at low or no-profit prices. In 2011, a group of interested pharmaceutical companies, HIV experts, international organisations and policy-makers convened in London to discuss how this could be done and commissioned research into a potential operating model. The outcomes are discussed in this report.

Malaria Report

Staying the course? Malaria research and development in a time of economic uncertainty (2011)

Malaria continues to place an enormous economic and health burden on developing countries, where more than three-quarters of a million deaths occur each year. Although the last decade has seen progress in malaria R&D—and we are now on the way to achieving global malaria control, treatment and elimination goals—these gains are fragile, and may be reversed if funding drops.

This report provides detailed analysis of malaria R&D funding data from 2004-2009. The report:

  • Identifies whether R&D funding is likely to meet and match projected needs
  • Pinpoints which product areas are receiving sufficient investment and which areas need their funding ramped up in order make the necessary new products available

Vaccine pipelines, bottlenecks and collaborations (2011)

We have been commissioned by GAVI to investigate and provide a landscape analysis of vaccines in clinical development to support GAVI’s strategic goal of shaping vaccine markets with regard to pricing and supply security and making catalytic investments to facilitate introduction of appropriate vaccines.

This involved analysis of vaccine pipelines for pneumonia, rotavirus, dengue, malaria and typhoid; identification of bottlenecks to vaccine development and production; examples of collaborative efforts to overcome these bottlenecks; and analysis of gap areas where new initiatives are needed to expedite the vaccine pipeline.

Malaria Report

Registering new drugs: The African context (2010)

Regulatory processes can cause major delays in African patients receiving new neglected disease drugs. This report identifies hurdles to safe rapid drug registration for African use, and suggests solutions to streamline regional and international regulatory policy.

Malaria Report

Strengthening pharmaceutical innovation in Africa (2009)

African governments face a plethora of challenges in achieving medicines access for their populations, either by importation, local manufacture or local research and development into new products. Working with developing world partners, we developed a decision-making tool and supporting documents to guide African government investment into pharmaceutical innovation.

Malaria Report

The malaria product pipeline: planning for the future (2007)

Rapid development of the malaria product pipeline has led to fears of clinical trial capacity overload and funding shortfalls. Liaising closely with African and Western trial sites and malaria product developers, this report analyses malaria trial site demand and supply, and quantifies funding demand for malaria drug and vaccine development.

Malaria Report

The new landscape of neglected disease drug development (2005)

Prior to 2005, there was a widespread belief that little was happening in neglected disease R&D and scepticism over the roles of Product Development Partnerships and industry. By analysing portfolios and business models, this report demonstrated a burgeoning product pipeline, identified the main players and mapped out new business models and incentives to support this.

 

Sydney

Suite 206, 68 York Street,
Sydney 2000, Australia
Tel: +61 2 9262 5211
Fax: +61 2 9262 5233
Email: